M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial

Phase 2

Recruiting

Conditions: Intra-abdominal Cancer

Interventions: Drug: Hydrocodone
Drug: Tramadol
Drug: Oxycodone

First Posted Date: 2024-01-31

Last Posted Date: 2024-05-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 150

Registration Number: NCT06232577

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

Phase 2

Recruiting

Conditions: Leukemia
HOX Gene

Interventions: Drug: Revumenib

First Posted Date: 2024-01-29

Last Posted Date: 2024-06-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT06229912

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.

Phase 2

Recruiting

Conditions: Lymphoma

Interventions: Procedure: Chemotherapy
Drug: Fecal Microbiota Transplantation
Procedure: CAR-T Therapy

First Posted Date: 2024-01-23

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06218602

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Ultrasound-guided Peripheral Intravenous Catheter Placement in an Oncologic Emergency Department - a Prospective, Randomized Controlled Trial of Catheter Lengths

Not Applicable

Recruiting

Conditions: Oncologic Complications and Emergencies

Interventions: Device: Introcan Safety IV Catheter

First Posted Date: 2024-01-22

Last Posted Date: 2024-10-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 400

Registration Number: NCT06217783

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Phase 2

Recruiting

Conditions: B Cell Lymphoma

Interventions: Drug: Glofitamab
Drug: Obinutuzumab
Drug: Axi-cel

First Posted Date: 2024-01-19

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06213311

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis

Recruiting

Conditions: Lymphomatoid Papulosis
Mycosis Fungoides

First Posted Date: 2024-01-17

Last Posted Date: 2024-07-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT06207812

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Phase 2

Recruiting

Conditions: Post-transplant MRD-guided Maintenance Therapy
Multiple Myeloma
Pre-transplant Purging

Interventions: Drug: Elranatamab
Drug: Lenalidomide
Drug: Plerixafor
Drug: Melphalan
Drug: Busulfan
Drug: G-CSF
Procedure: Stem cell transplant

First Posted Date: 2024-01-17

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06207799

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

Phase 1

Recruiting

Conditions: Metastatic Appendiceal Adenocarcinoma
Intraperitoneal Paclitaxel

Interventions: Drug: Dexamethasone
Drug: Diphenhydramine
Drug: Famotidine
Drug: Paclitaxel

First Posted Date: 2024-01-16

Last Posted Date: 2024-07-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT06207305

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Risk Adapted Spinal Cord/Cauda Constraint Relaxation for High-risk Patients With Metastatic Epidural Spinal Cord Compression Undergoing Spine Stereotactic Radiosurgery

Phase 2

Recruiting

Conditions: Spine Stereotactic
Spinal Cord
Metastatic Epidural

Interventions: Radiation: Stereotactic Radiosurgery

First Posted Date: 2024-01-12

Last Posted Date: 2024-11-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT06204315

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

Phase 2

Recruiting

Conditions: Depression, Anxiety
Psilocybin-Assisted Psychotherapy
Advanced Cancer

Interventions: Drug: Psilocybin
Other: Niacin

First Posted Date: 2024-01-10

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT06200155

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy